These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 25600203)

  • 1. Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans.
    Jayaraman R; Pasha MK; Williams A; Goh KC; Ethirajulu K
    Drug Metab Lett; 2015; 9(1):28-47. PubMed ID: 25600203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
    Pasha MK; Jayaraman R; Reddy VP; Yeo P; Goh E; Williams A; Goh KC; Kantharaj E
    Drug Metab Lett; 2012 Mar; 6(1):33-42. PubMed ID: 22372550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
    Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
    Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
    Dowty ME; Lin J; Ryder TF; Wang W; Walker GS; Vaz A; Chan GL; Krishnaswami S; Prakash C
    Drug Metab Dispos; 2014 Apr; 42(4):759-73. PubMed ID: 24464803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys.
    Christopher LJ; Cui D; Li W; Barros A; Arora VK; Zhang H; Wang L; Zhang D; Manning JA; He K; Fletcher AM; Ogan M; Lago M; Bonacorsi SJ; Humphreys WG; Iyer RA
    Drug Metab Dispos; 2008 Jul; 36(7):1341-56. PubMed ID: 18420785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics.
    Jayaraman R; Pilla Reddy V; Pasha MK; Wang H; Sangthongpitag K; Yeo P; Hu CY; Wu X; Xin L; Goh E; New LS; Ethirajulu K
    Drug Metab Dispos; 2011 Dec; 39(12):2219-32. PubMed ID: 21873472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo metabolism of a selective δ-opioid receptor.
    Guo J; Gu C; Zhou D; Elmore CS; Bui KH; Grimm SW
    Drug Metab Dispos; 2011 Oct; 39(10):1883-94. PubMed ID: 21752944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro metabolism of BIIB021, an inhibitor of heat shock protein 90, in liver microsomes and hepatocytes of rats, dogs, and humans and recombinant human cytochrome P450 isoforms.
    Xu L; Woodward C; Khan S; Prakash C
    Drug Metab Dispos; 2012 Apr; 40(4):680-93. PubMed ID: 22217465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.
    Takahashi RH; Choo EF; Ma S; Wong S; Halladay J; Deng Y; Rooney I; Gates M; Hop CE; Khojasteh SC; Dresser MJ; Musib L
    Drug Metab Dispos; 2016 Jan; 44(1):28-39. PubMed ID: 26451002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of transgenic mouse models to understand the oral disposition and drug-drug interaction potential of cobimetinib, a MEK inhibitor.
    Choo EF; Woolsey S; DeMent K; Ly J; Messick K; Qin A; Takahashi R
    Drug Metab Dispos; 2015 Jun; 43(6):864-9. PubMed ID: 25813936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite.
    Dowty ME; Qiu R; Dantonio A; Niosi M; Doran A; Balesano A; Wright SW; Walker GS; Sharma R
    Drug Metab Dispos; 2024 Jun; 52(7):690-702. PubMed ID: 38719744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
    Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
    J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the disposition of a novel p38 MAPK inhibitor, AKP-001, and its metabolites in rats with a simple physiologically based pharmacokinetic model.
    Shirota K; Kaneko M; Sasaki M; Minato K; Fujikata A; Ohta S; Hisaka A; Suzuki H
    Drug Metab Dispos; 2015 Feb; 43(2):217-26. PubMed ID: 25422274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.
    Dickinson PA; Cantarini MV; Collier J; Frewer P; Martin S; Pickup K; Ballard P
    Drug Metab Dispos; 2016 Aug; 44(8):1201-12. PubMed ID: 27226351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
    Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
    Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
    Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
    Glaenzel U; Jin Y; Hansen R; Schroer K; Rahmanzadeh G; Pfaar U; Jaap van Lier J; Borell H; Meissner A; Camenisch G; Zhao S
    Drug Metab Dispos; 2020 Oct; 48(10):873-885. PubMed ID: 32665418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.